Source: Virtual Congress 2020 – Rethinking asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Nair (Hamilton (ON), Canada). Is severe neutrophilic asthma a separate entity?:Con. Virtual Congress 2020 – Rethinking asthma

Member's Comments

No comment yet.

Related content which might interest you: Neutrophilic severe asthma Source: International Congress 2015 – Severe asthma phenotyping Year: 2015 Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Neutrophilic inflammation in severe asthmatics and COPD patients with the same severity of airway obstruction Source: Eur Respir J 2002; 20: Suppl. 38, 505s Year: 2002 Mepolizumab in real-life treatment of severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 The role of neutrophilic inflammation in asthma of different severity Source: Eur Respir J 2002; 20: Suppl. 38, 310s Year: 2002 Benralizumab for severe asthma associated with extra-airway eosinophilic diseases Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Late-onset persistent eosinophilic severe asthma Source: International Congress 2015 – Severe asthma phenotyping Year: 2015 Role of neutrophils in airway inflammation in children with severe persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 142s Year: 2002 The ERS/EAACI statement on severe exacerbations of asthma, and how to deal with non-allergic severe asthma Source: International Congress 2019 – Pathophysiology and clinical insights into severe non-allergic asthma Year: 2019 Mast cells are associated with exacerbations and eosinophilia in children with severe asthma Source: Eur Respir J 2016; 48: 1320-1328 Year: 2016 IL-33 in patients with severe uncontrolled allergic asthma Source: International Congress 2017 – "Alarming" immunological patterns in asthma Year: 2017 Pathophysiology of non-eosinophilic severe asthma Source: International Congress 2017 – Pathophysiology and emerging therapies for severe asthma Year: 2017 The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia Source: Eur Respir J 2014; 44: 239-241 Year: 2014 The importance of eosinophilic inflammation in COPD exacerbations Source: International Congress 2017 – COPD management Year: 2017 Airway inflammation in non-eosinophilic atopic asthma: comparisons with eosinophilic atopic asthma and COPD Source: Eur Respir J 2005; 26: Suppl. 49, 733s Year: 2005 Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Acceleration of neutrophilic inflammation during COPD exacerbation Source: Eur Respir J 2002; 20: Suppl. 38, 505s Year: 2002 Eosinophilic refractory inflammation in OCS-dependent severe asthma Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Conclusion: clinical phenotypes of asthma Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005